Can the sequential use of conventional silicone oil and heavy oil be a strategy for the management of proliferative vitreoretinopathy?

Annals of the Academy of Medicine Singapore

Volumn 35, Issue 3, 2006, Pages 181-184

  Wong, David ^a   Cazabon, Sunildath ^a   Ali, Haslina ^a   Kumar, Indu ^a   Valldeperas, Xavier ^a   Groenewald, Carl ^a   Pearce, Ian ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Densiron; Retinal detachment; Retinotomy; Silicone oil; Vitrectomy

Indexed keywords

SILICONE OIL;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; LENS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; RETINA DETACHMENT; RETINOPATHY; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY;

EID: 33745192821     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Sharma T, Gopal L. Recent developments in vitreoretinal surgery. J Indian Med Assoc 2000;98:754-2.
2. Chang S. Low viscosity liquid fluorochemicals in vitreous surgery. Am. J Ophthalmol 1987;103:38-43.
3. Chang S, Ozmert E, Zimmerman NJ. Intraoperative perfluorocarbon liquids in the management of proliferative vitreoretinopathy. Am J Ophthalmol 1988;106:668-74.
4. Spitznas M, Reiner J. A stereoscopic diagonal inverter (SDI) for wide-angle vitreous surgery. Graefes Arch Clin Exp Ophthalmol 1987;225:9-12.
5. Spitznas M. A binocular indirect ophthalmomicroscope (BIOM) for non-contact wide-angle vitreous surgery. Graefes Arch Clin Exp Ophthalmol 1987;225:13-5.
6. Feron EJ, Veckeneer M, Parys-Van Ginderdeuren R, Van Lommel A, Melles GR, Stalmans P. Trypan blue staining of epiretinal membranes in proliferative vitreoretinopathy. Arch Ophthalmol 2002;120:141-4.
7. Teba FA, Mohr A, Eckardt, Wong D, Kusaka S, Joondeph BC, et al. Trypan blue staining in vitreoretinal surgery. Ophthalmology 2003;110:2409-12.
8. Falkner CI, Binder S, Kruger A. Outcome after silicone oil removal. Br J Ophthalmol 2001;85:1324-7.
9. Scott IU, Flynn HW Jr, Lai M, Chang S, Azen SP. First operation anatomic success and other predictors of postoperative vision after complex retinal detachment repair with vitrectomy and silicone oil tamponade. Am J Ophthalmol 2000;130:745-50.
10. Scott IU, Flynn HW Jr, Murray TG, Feuer WJ; Perfluoron Study Group. Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter study. Am J Ophthalmol 2003;136:454-63.
11. Wetterqvist C, Wong D, Williams R, Stappler T, Herbert E, Freeburn S. Tamponade efficiency of perfluorohexyloctane and silicone oil solutions in a model eye chamber. Br J Ophthalmol 2004;88:692-6.
12. Wong D, Williams R, Stappler T, Groenewald C. What pressure is exerted on the retina by heavy tamponade agents? Graefes Arch Clin Exp Ophthalmol 2005;243:474-7.
13. Wong D, Van Meurs JC, Stappler T, Groenewald C, Pearce IA, McGalliard JN, et al. A pilot study on the use of a perfluorohexyloctane/silicone oil solution as a heavierthan water internal tamponade agent. Br J Ophthalmol 2005;89:662-5.
14. Herbert E, Stappler T, Wetterqvist C, Williams R, Wong D. Tamponade properties of double-filling with perfluorohexyloctane and silicone oil in a model eye chamber. Graefes Arch Clin Exp Ophthalmol 2004;242:250-4.
15. Fawcett IM, Williams RL, Wong D. Contact angles of substances used for internal tamponade in retinal detachment surgery. Graefes Arch Clin Exp Ophthalmol 1994;232:438-44.
16. Kirchhof B, Wong D, Van MJ, Hilgers RD, Macek M, Lois N, et al. Use of perfluorohexyloctane as a long-term internal tamponade agent in complicated retinal detachment surgery. Am J Ophthalmol 2002;133:95-101.
17. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial. Ophthalmology 2001;108:1179-83.
18. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Luthert PJ, et al. How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology 2001;108:1184-6.
19. Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RH, Bunce C, et al. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 2004;111:2240-5.
20. Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol 1998;126:550-9.
21. Wiedemann P, Leinung C, Hilgers RD, Heimann K. Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 1991;229:150-2.
22. Asaria RH, Kon CH, Bunce C, Sethi CS, Limb GA, Khaw PT, et al. Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid. Br J Ophthalmol 2004;88:1439-42.